These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25894719)

  • 21. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
    Vogel CL; Wojtukiewicz MZ; Carroll RR; Tjulandin SA; Barajas-Figueroa LJ; Wiens BL; Neumann TA; Schwartzberg LS
    J Clin Oncol; 2005 Feb; 23(6):1178-84. PubMed ID: 15718314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers.
    Zhang W; Tyrrell H; Ding HT; Pulley J; Boruvka A; Erickson R; Abouhossein M; Ravanello R; Tang MT
    Adv Ther; 2021 May; 38(5):2418-2434. PubMed ID: 33778929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects.
    Struemper H; Murtaugh T; Gilbert J; Barton ME; Fire J; Groark J; Fox NL; Roth D; Gordon D
    Clin Pharmacol Drug Dev; 2016 May; 5(3):208-15. PubMed ID: 27163500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
    Singh I; Attrey A; Garg A; Patel R; Jose V
    Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.
    Metz M; Semsek D; Rogmans G; Hutzschenreuter U; Fietz T; Harde J; Zacharias S; Hielscher C; Lorenz A; Zahn MO; Guth D; Liebers S; Berghorn M; Grebhardt S; Matillon CD; Egerer G; Potthoff K
    Support Care Cancer; 2021 Nov; 29(11):6633-6643. PubMed ID: 33956213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe.
    Cherniakov I; Cohen-Barak O; Tiver R; Gillespie M; Kessler Y; Gutierrez M; Rasamoelisolo M; Li S; Shen H; Hallak H; Loupe PS; Smith M; Rabinovich-Guilatt L; Spiegelstein O
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1018-1027. PubMed ID: 33411992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis.
    McBride A; Campbell K; Li E; Schroader B; Campbell D; Wang W
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1230-1238. PubMed ID: 33929269
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects.
    Shin D; Lee Y; Jeong D; Ellis-Pegler R
    Drug Des Devel Ther; 2018; 12():3799-3805. PubMed ID: 30464411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector.
    Xu Z; Marciniak SJ; Frederick B; Kim L; Zhuang Y; Davis HM; Zhou H
    Clin Ther; 2015 Feb; 37(2):427-38. PubMed ID: 25438720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
    Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegfilgrastim administered in an abbreviated schedule, significantly improved neutrophil recovery after high-dose radiation-induced myelosuppression in rhesus macaques.
    Farese AM; Cohen MV; Stead RB; Jackson W; Macvittie TJ
    Radiat Res; 2012 Nov; 178(5):403-13. PubMed ID: 22991919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
    Davidson A; Brimhall D; Kay J; Keystone E; Lee SJ; Kim SH; Bae YJ; Choi EJ; Furst DE
    Br J Clin Pharmacol; 2021 Nov; 87(11):4323-4333. PubMed ID: 33822406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic administration of pegfilgrastim instead of prophylactic use.
    Stathopoulos GP; Dimou E; Stathopoulos J; Xynotroulas J
    Anticancer Res; 2005; 25(3c):2445-8. PubMed ID: 16080473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study.
    Noga SJ; Choksi JK; Ding B; Dreiling L; Ozer H
    Clin Lymphoma Myeloma; 2007 May; 7(6):413-20. PubMed ID: 17621407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
    Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
    Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
    Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P
    Clin Ther; 2011 Jun; 33(6):776-91. PubMed ID: 21704242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative Bioavailability Study of Midazolam Intramuscularly Administered with the Needle-Free Auto-Injector ZENEO
    Lacombe O; Pletan Y; Grouin JM; Brennan A; Giré O
    Neurol Ther; 2024 Aug; 13(4):1155-1172. PubMed ID: 38806873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects.
    Cox DS; Alvarez DF; Bock AE; Cronenberger CL
    Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1166-1173. PubMed ID: 33765358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.